The Brazilian health agency Anvisa has issued a warning regarding the consumption of turmeric supplements, stating that they may cause liver inflammation and damage. This alert follows international investigations that identified rare but potentially severe cases of liver-related issues due to the intake of concentrated turmeric extracts. Anvisa emphasizes the safety of turmeric used in food as a seasoning, but highlights the risks associated with products that contain high doses of the compound.

In response to this potential health risk, Anvisa has mandated updates to the safety information provided on medication packaging. Specifically, the agency is requiring that labels on turmeric-containing supplements include clear warnings about the possibility of adverse effects. This proactive measure aims to protect consumers and ensure they are informed about the risks before using such products.

Furthermore, other countries such as Italy, Australia, Canada, and France have also issued similar warnings after reporting cases of liver intoxication linked to turmeric supplement consumption. This situation underscores the importance of regulatory oversight on dietary supplements and the need for consumers to be wary of high-dose products that may pose health risks.